Boston Oncology CGT Holding to license Xuanzhu Biopharmaceutical’s Bireociclib and Dirozalkib
Cambridge, Massachusetts-based oncology drugmaker Boston Oncology CGT Holding will license Xuanzhu Biopharmaceutical’s breast cancer treatment Bireociclib and lung cancer treatment Dirozalkib, making payments exceeding $100 million if milestones are met, the Chinese drugmaker said Thursday. Both drugs are approved in China. The deal’s execution “is an important strategic initiative for the Group in its global market expansion,” Xuanzhu said in a filing to the Hong Kong stock exchange.
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.